Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells
Rebecca L. Lloyd, Paul W.G. Wijnhoven, Antonio Ramos‐Montoya, et al.
Oncogene (2020) Vol. 39, Iss. 25, pp. 4869-4883
Open Access | Times Cited: 152

Showing 1-25 of 152 citing articles:

Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer
Marilyne Labrie, Joan S. Brugge, Gordon B. Mills, et al.
Nature reviews. Cancer (2022) Vol. 22, Iss. 6, pp. 323-339
Open Access | Times Cited: 227
Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments
Hon Yan Kelvin Yip, Antonella Papa
Cells (2021) Vol. 10, Iss. 3, pp. 659-659
Open Access | Times Cited: 205
Targeting telomeres: advances in telomere maintenance mechanism-specific cancer therapies
Jixuan Gao, Hilda A. Pickett
Nature reviews. Cancer (2022) Vol. 22, Iss. 9, pp. 515-532
Closed Access | Times Cited: 139
ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib
Zena Wilson, Rajesh Odedra, Yann Wallez, et al.
Cancer Research (2022) Vol. 82, Iss. 6, pp. 1140-1152
Open Access | Times Cited: 81
Targeted Therapy and Mechanisms of Drug Resistance in Breast Cancer
Briana Kinnel, Santosh Kumar Singh, Gabriela Oprea‐Ilies, et al.
Cancers (2023) Vol. 15, Iss. 4, pp. 1320-1320
Open Access | Times Cited: 77
Targeting ATR in patients with cancer
Natalie Ngoi, Patrick G. Pilié, Daniel J. McGrail, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 4, pp. 278-293
Closed Access | Times Cited: 24
When DNA-damage responses meet innate and adaptive immunity
Jie Tong, Jiangwei Song, Wuchao Zhang, et al.
Cellular and Molecular Life Sciences (2024) Vol. 81, Iss. 1
Open Access | Times Cited: 20
RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors
Anne Roulston, Michal Zimmermann, Robert Papp, et al.
Molecular Cancer Therapeutics (2021) Vol. 21, Iss. 2, pp. 245-256
Open Access | Times Cited: 65
PARP1: Structural insights and pharmacological targets for inhibition
Jacob O. Spiegel, Bennett Van Houten, Jacob D. Durrant
DNA repair (2021) Vol. 103, pp. 103125-103125
Open Access | Times Cited: 63
The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment
Shuangying Li, Liangliang Wang, Yuanyuan Wang, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 63
cGAS/STING cross-talks with cell cycle and potentiates cancer immunotherapy
Zi‐Jie Long, Jundan Wang, Jue‐Qiong Xu, et al.
Molecular Therapy (2022) Vol. 30, Iss. 3, pp. 1006-1017
Open Access | Times Cited: 49
PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers
Linjie Luo, Khandan Keyomarsi
Expert Opinion on Investigational Drugs (2022) Vol. 31, Iss. 6, pp. 607-631
Open Access | Times Cited: 47
ATM: Functions of ATM Kinase and Its Relevance to Hereditary Tumors
Sayaka Ueno, Tamotsu Sudo, Akira Hirasawa
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 1, pp. 523-523
Open Access | Times Cited: 40
PARP inhibitors in metastatic prostate cancer
Amy K. Taylor, David Kosoff, Hamid Emamekhoo, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 38
Targeting ATM and ATR for cancer therapeutics: Inhibitors in clinic
Bhanu Priya, Srimadhavi Ravi, Sivapriya Kirubakaran
Drug Discovery Today (2023) Vol. 28, Iss. 8, pp. 103662-103662
Closed Access | Times Cited: 33
Emerging strategies for cancer therapy by ATR inhibitors
Kimiyoshi Yano, Bunsyo Shiotani
Cancer Science (2023) Vol. 114, Iss. 7, pp. 2709-2721
Open Access | Times Cited: 29
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment
Elizabeth Hardaker, Emilio Sanseviero, Ankur Karmokar, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 13
DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications
Yvette Drew, Frank T. Zenke, Nicola J. Curtin
Nature Reviews Drug Discovery (2024) Vol. 24, Iss. 1, pp. 19-39
Closed Access | Times Cited: 12
Semi-mechanistic efficacy model for PARP + ATR inhibitors—application to rucaparib and talazoparib in combination with gartisertib in breast cancer PDXs
Claire C. Villette, Nathalie Dupuy, Frances A. Brightman, et al.
British Journal of Cancer (2025)
Open Access | Times Cited: 1
Simulations probe the role of space in the interplay between drug-sensitive and drug-resistant cancer cells
Kira Pugh, Rhys D.O. Jones, Gibin Powathil, et al.
Journal of Theoretical Biology (2025), pp. 112048-112048
Open Access | Times Cited: 1
<p>PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date</p>
Emily Nizialek, Emmanuel S. Antonarakis
Cancer Management and Research (2020) Vol. Volume 12, pp. 8105-8114
Open Access | Times Cited: 70
Targeting DNA Damage Response in Prostate and Breast Cancer
Antje M. Wengner, Arne Scholz, Bernard Haendler
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 21, pp. 8273-8273
Open Access | Times Cited: 70
Synthetic lethality strategies: Beyond BRCA1/2 mutations in pancreatic cancer
Yunlong Hu, Mingzhou Guo
Cancer Science (2020) Vol. 111, Iss. 9, pp. 3111-3121
Open Access | Times Cited: 61
Targeting the DNA Damage Response to Overcome Cancer Drug Resistance in Glioblastoma
Alessandra Ferri, Venturina Stagni, Daniela Barilà
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 14, pp. 4910-4910
Open Access | Times Cited: 60
Guiding ATR and PARP inhibitor combinations with chemogenomic screens
Michal Zimmermann, Cynthia Bernier, Beatrice Kaiser, et al.
Cell Reports (2022) Vol. 40, Iss. 2, pp. 111081-111081
Open Access | Times Cited: 37
Page 1 - Next Page

Scroll to top